Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.

Jeon S, Juhn JH, Han S, Lee J, Hong T, Paek J, Yim DS.

J Transl Med. 2013 Oct 2;11:240. doi: 10.1186/1479-5876-11-240.

PMID:
24088361
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.

García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA; FarmaPEG Study Group.

BMC Pharmacol. 2010 Nov 23;10:15. doi: 10.1186/1471-2210-10-15.

PMID:
21092287
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK.

Cancer Chemother Pharmacol. 2011 Mar;67(3):657-66. doi: 10.1007/s00280-010-1326-9. Epub 2010 May 28.

PMID:
20509027
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.

Mager DE, Neuteboom B, Jusko WJ.

Pharm Res. 2005 Jan;22(1):58-61.

PMID:
15771230
[PubMed - indexed for MEDLINE]
5.

In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.

Hu X, Olivier K, Polack E, Crossman M, Zokowski K, Gronke RS, Parker S, Li Z, Nestorov I, Baker DP, Clarke J, Subramanyam M.

J Pharmacol Exp Ther. 2011 Sep;338(3):984-96. doi: 10.1124/jpet.111.180661. Epub 2011 Jun 20.

PMID:
21690216
[PubMed - indexed for MEDLINE]
Free Article
6.

Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys.

Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ.

J Pharmacol Exp Ther. 2003 Jul;306(1):262-70. Epub 2003 Mar 26.

PMID:
12660309
[PubMed - indexed for MEDLINE]
Free Article
7.

Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans.

Mager DE, Jusko WJ.

Pharm Res. 2002 Oct;19(10):1537-43.

PMID:
12425473
[PubMed - indexed for MEDLINE]
8.

Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by peg-interferon-alpha 2a.

Saito T, Iida S, Kawanishi T.

Drug Metab Pharmacokinet. 2012;27(6):614-20. Epub 2012 Jun 12.

PMID:
22785255
[PubMed - indexed for MEDLINE]
Free Article
9.

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM.

Br J Clin Pharmacol. 1998 Dec;46(6):563-70.

PMID:
9862245
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.

Brennan BJ, Xu ZX, Grippo JF.

Clin Ther. 2012 Sep;34(9):1883-91. doi: 10.1016/j.clinthera.2012.07.003. Epub 2012 Aug 1.

PMID:
22858176
[PubMed - indexed for MEDLINE]
11.

Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation.

Brearley C, Jaber A, Bertolino M, Priestley A, Seiberling M.

Int J Clin Pharmacol Ther. 2007 Jun;45(6):307-18.

PMID:
17595888
[PubMed - indexed for MEDLINE]
12.

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.

Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H.

Clin Cancer Res. 2005 Sep 1;11(17):6247-55.

PMID:
16144928
[PubMed - indexed for MEDLINE]
Free Article
13.

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

Stürzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B.

J Interferon Cytokine Res. 1999 Nov;19(11):1257-64.

PMID:
10574618
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.

Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M.

Clin Pharmacokinet. 2009;48(8):543-54. doi: 10.2165/11317180-000000000-00000.

PMID:
19705924
[PubMed - indexed for MEDLINE]
15.

Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.

Scagnolari C, Casato M, Bellomi F, De Pisa F, Turriziani O, Coviello R, Pirro MR, Dianzani F, Antonelli G.

Clin Diagn Lab Immunol. 2003 Jan;10(1):70-7.

PMID:
12522042
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L.

J Clin Oncol. 2001 Mar 1;19(5):1312-9.

PMID:
11230473
[PubMed - indexed for MEDLINE]
17.

Estimation of absorption rate of alpha-human atrial natriuretic peptide from the plasma profile and diuretic effect after intranasal administration to rats.

Miyamoto M, Tsukune T, Hori S, Hayashi T, Natsume H, Sugibayashi K, Morimoto Y.

Biopharm Drug Dispos. 2001 May;22(4):137-46.

PMID:
11745916
[PubMed - indexed for MEDLINE]
18.

Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.

Katayama K, Kasahara A, Sasaki Y, Kashiwagi T, Naito M, Masuzawa M, Katoh M, Yoshihara H, Kamada T, Mukuda T, Hijioka T, Hori M, Hayashi N.

J Viral Hepat. 2001 May;8(3):180-5.

PMID:
11380795
[PubMed - indexed for MEDLINE]
19.

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.

Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G.

J Clin Pharmacol. 2012 Jun;52(6):798-808. doi: 10.1177/0091270011407068. Epub 2011 Jun 16. Erratum in: J Clin Pharmacol. 2012 Sep;52(9):NP4-5.

PMID:
21680782
[PubMed - indexed for MEDLINE]
20.

Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK.

J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):321-42.

PMID:
11677930
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk